Close search

Fladgate advises Huma Therapeutics Limited on its acquisitions of Tarilian Laser Technologies Limited and Biobeats Group Limited

Fladgate LLP has advised Huma Therapeutics Limited (formerly Medopad Ltd), a leading London based health technology startup that builds software for the remote monitoring of patients and develops digital biomarkers and therapeutics, on its strategic acquisitions of blood pressure monitoring specialist Tarilian Laser Technologies Limited and mental health focused Biobeats Group Limited.

Huma has achieved significant success in the health technology sector, including working closely with the government health ministries to help combat the coronavirus pandemic by providing remote patient monitoring capabilities.

The Fladgate team was led by Corporate partners Grant Gordon and Jeremy Whiteson, who worked with Tax partner Hamilton Forrest, Employment partner Mike Tremeer.

Commenting on the transaction, corporate partner Jeremy Whiteson said: “We are delighted to have been able to help Huma on these two recent acquisitions. They are an exciting company whose thinking is at the forefront of delivery of patient diagnosis and treatment, highlighted by the need for remotely accessed medical applications in the Covid-19 crisis”. Relationship partner Grant Gordon added: “We have been hugely impressed by Huma as an organisation and by the people driving its market-leading vision and strategy and are pleased to be assisting in the delivery and execution of its ambitious growth plans that go well beyond the immediate crisis”.

Dan Vahdat, CEO of Huma, commented: “We have been impressed by our work with the Fladgate team, whose solution-orientated approach has added real value to Huma”.

Featured Insights


Contact us